New scanner could halve repeat breast cancer surgeries

NCT ID NCT07527468

First seen Apr 17, 2026 · Last updated Jun 20, 2026 · Updated 8 times

Summary

This study tests a special scanner that lets surgeons check, in real time during breast cancer surgery, whether all cancer has been removed. The goal is to reduce the need for a second operation. About 228 women with certain high-risk breast cancer types will take part. The scanner is already approved for use, and this study will see if it cuts the repeat surgery rate from about 11% to 5% or less.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Centre Hospitalier du Valais Romand (CHVR)

    Sion, Valais, 1950, Switzerland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Email: •••••@•••••

    Contact

    Contact

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Histolog Scanner (a confocal fluorescence microscopy device used during surgery to check if all cancer has been removed)

What this could lead to

If successful, this device could help surgeons remove all cancer in one operation, reducing the need for a second surgery and its associated stress and recovery time.

What could go wrong

This is a relatively small, single-center study comparing results to past cases, not a randomized trial. The device may not work as well in all patients or tumor types, and the final decision for reoperation is made independently, so the device's impact may be limited.

Conditions

The condition(s) this trial relates to.

breast neoplasm Carcinoma, Lobular ductal breast carcinoma in situ Margins of Excision

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.